Mycovia Pharmaceuticals Inc.   Report issue

Contributed to NME For profit Phase 3
Founded: Durham NC United States (2018)

Organization Overview

First Clinical Trial
2018
NCT03562156
First Marketed Drug
2022
oteseconazole (Vivjoa)
First NDA Approval
2022
oteseconazole (Vivjoa)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Mycovia Pharmaceuticals Inc. | MYCOVIA PHARMS

Active Ingredients

Marketed Drugs (1)

oteseconazole (Vivjoa) (2022 NDA)

Drugs in Phase 3 Trials (2)

fluconazole (diflucan) (1 trial)

oteseconazole (Vivjoa) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidiasis (Phase 3)

Candidiasis, Vulvovaginal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2